Effect of N-acetyl cysteine on hepatitis risk reduction after anesthesia

Comparison of N-acetyl cysteine vs saline on liver function on general anesthesia with isoflurane in Arak Vali-e-Asr hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014091919199N2

Enrollment

Registered

2015-04-12

Start date

2014-04-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver toxicity. Toxic liver disease

Interventions

Intervention 1: In intervention group patients will receive 150 mg/kg N-Acetyl cysteine with 250 ml normal saline in single IV dose and isoflurane will be used for maintenance anesthesia. We injected

Treatment - Drugs

In intervention group patients will receive 150 mg/kg N-Acetyl cysteine with 250 ml normal saline in single IV dose and isoflurane will be used for maintenance anesthesia. We injected above mentioned

In control group patients will receive only 250 ml normal salinein single IV dose and isoflurane will used for maintenance anesthesia.we injected above solution before induction.All patients will pre-

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 20 and 60 years old; ASA I or II; Elective surgery took 1-3 hours(except surgery on the liver and biliary tract). Exclusion: Underlying cardiovascular, pulmonary , renal , hepatic , endocrine diseases; Taking warfarin , aspirin , NSAIDS, vitamins, corticosteroids, Immuno-Suppressive Drug or any medications interfere with liver function;History of drug abuse, alcohol, cigarettes; History of hepatitis C, B; History of IBD, malabsorption; history of abdominal surgery 5 years ago.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
AST. Timepoint: Before surgery, 1 and 24 h after it. Method of measurement: With MAK055 Sigma laboratory kit.;ALT. Timepoint: Before surgery, 1 and 24 h after it. Method of measurement: With MAK052 Sigma laboratory kit.;LDH. Timepoint: Before surgery, 1 and 24 h after it. Method of measurement: With MAK066 Sigma laboratory kit.	—

Secondary

Measure	Time frame
PT. Timepoint: Before surgery, 1 and 24 h after it. Method of measurement: PT kit \ medical diagnosis laboratory.;PTT. Timepoint: Before surgery, 1 and 24 h after it. Method of measurement: Stago PTT laboratory kit.;Mean arterial pressure. Timepoint: before and after induction, after intubation and every 10 minute. Method of measurement: sphygmomanometer.;Heart rate. Timepoint: before and after induction, after intubation and every 10 minute. Method of measurement: measuring the number of times their heart beats each minute by touching the pulse.;O2 saturation. Timepoint: before and after induction, after intubation and every 10 minute. Method of measurement: measuring of o2 saturation by pulse oximetry.	—

Measure

Time frame

PT. Timepoint: Before surgery, 1 and 24 h after it. Method of measurement: PT kit \ medical diagnosis laboratory.;PTT. Timepoint: Before surgery, 1 and 24 h after it. Method of measurement: Stago PTT laboratory kit.;Mean arterial pressure. Timepoint: before and after induction, after intubation and every 10 minute. Method of measurement: sphygmomanometer.;Heart rate. Timepoint: before and after induction, after intubation and every 10 minute. Method of measurement: measuring the number of times their heart beats each minute by touching the pulse.;O2 saturation. Timepoint: before and after induction, after intubation and every 10 minute. Method of measurement: measuring of o2 saturation by pulse oximetry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Saber Akhtaran

Arak University of Medical Sciences

dr.akhtaran@arakmu.ac.ir+98 86 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026